Timothy Kelley

Timothy Kelley

Sometimes the private murmurs in the audience can be just as informative as the pronouncements from the authorities up on stage. That was my experience last month, when I went to Boston to take in a session of a Harvard School of Public Health conference on health care alliances.

The discussion featured 10 health care industry leaders of varying ideological stripes and one facilitator, the engaging Harvard Law School Prof. Charles R. Nesson, J.D. The issue was health care as a profit-making enterprise, and if Nesson was there to draw the speakers out, it had to be admitted that they didn't need much drawing. Malik Hasan, M.D., chairman, president and CEO of Health Systems International, expanded on his own keynote address earlier in the morning to sing the inevitability of the free market, while longtime single-payer crusader Steffie Woolhandler, M.D., M.P.H., promptly announced her goal of putting Hasan and his ilk out of business. When the topic of the uninsured came up I wasn't sure whether Florence Nightingale's beneficence or Adam Smith's wisdom should guide me, but I knew my thoughts were lofty ones.

"We've always provided some charity care to the uninsured," said a Colorado physician to my left. "But if HMOs like Hasan's keep ratcheting down our pay, we won't be able to afford to."

Suddenly I saw the matter in a more practical light.

In this issue we print selections from that Harvard panel discussion — at least from the moments when everyone wasn't speaking at once — because we feel the topic gibes nicely with our cover article (p. 23) on the differences (and similarities) between for-profit and nonprofit health plans these days. In both we quote highly placed "experts," of course, but we hope you'll find their ideas sufficiently ballasted by testimony from physicians and HMO executives "in the trenches." If not, let us know, and perhaps we'll contact that Colorado doctor for a comment that cuts through the abstractions once again.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.